Table 3.
Cox’s proportional hazards model for predictors of overall survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age ≥ 65 years (vs. < 65 years) | 1.161 | 0.661-2.038 | 0.604 | |||
| Male gender (vs. female) | 0.886 | 0.375-2.095 | 0.783 | |||
| Viral etiology (vs. others) | 0.516 | 0.270-1.086 | 0.075 | |||
| Child-Pugh A (vs. B) | 0.671 | 0.150-1.083 | 0.065 | |||
| ALBI grade I (vs. II/III) | 0.539 | 0.305-0.952 | 0.033 | 0.382 | 0.180-0.810 | 0.012 |
| Macrovascular invasion (vs. no) | 2.848 | 1.632-4.969 | < 0.001 | 1.704 | 0.891-3.260 | 0.107 |
| Extrahepatic distant metastasis (vs. no) | 1.825 | 0.835-3.216 | 0.077 | |||
| BCLC stage B (vs. C) | 0.808 | 0.422-1.548 | 0.521 | |||
| AFP ≥ 400 ng/ml (vs. < 400) | 1.704 | 0.974-2.982 | 0.062 | |||
| Combination therapy (vs. no) | 0.607 | 0.310-0.889 | 0.045 | 0.726 | 0.347-1.522 | 0.397 |
| SII < 330 (vs. ≥ 330) | 0.402 | 0.188-0.860 | 0.019 | 0.485 | 0.231-0.820 | 0.037 |
| AE (vs. no) | 0.862 | 0.484-1.537 | 0.615 | |||
| Post-progression therapy (vs. no) | 0.481 | 0.243-0.955 | 0.037 | 0.613 | 0.286-1.313 | 0.208 |
Abbreviations: AE, adverse effect; AFP, alpha-fetoprotein; ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; SII, systemic inflammatory index.